Revisión y puesta al día en profundidad | 06 ENE 17

Enfermedad de hígado graso no alcohólico

Paralelo a la obesidad, la enfermedad por hígado graso no alcolólico y su progresión a esteatohepatitis se ha convertido en la enfermedad hepática más frecuente en niños y adolescentes
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas
  1. Vajro P, Lenta S, Socha P, Dhawan A, Mc Kiernan P, Baumann U, Durmaz O, Lacaille F, McLin V, Nobili V. Diagnosis of no­nalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gas­troenterol Nutr 2012; 54: 700-713.
  2. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009; 50: 1282-1293.
  3. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Ben­son JT, Enders FB, Angulo P. The natural history of non-alcoho­lic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538-1544.
  4. Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21: 11053-11076.
  5. Berardis S, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr 2014; 173: 131-139.
  6. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic stea­tohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
  7. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gas­troenterol 1983; 78: 374-377.
  8. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755.
  9. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974.
  10. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, Mc­Cullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
  11. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepato­logy 1990; 11: 74-80.
  12. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from stea­tosis to cirrhosis. Hepatology 2006; 43: S99-S112.
  13. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
  14. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NA­FLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
  15. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver di­sease and non-alcoholic steatohepatitis in adults. Aliment Phar­macol Ther 2011; 34: 274-285.
  16. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
  17. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365.
  18. Rafiq N, Bai C, Fang Y, Srishord M, Mc Cullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalco­holic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.
  19. Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, Mc Cullough A, Goodman Z, Younossi ZM. Predictors of all-cau­se mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013; 58: 3017-3023.
  20. Santoro N, Feldstein AE, Enoksson E, Pierpont B, Kursawe R, Kim G, Caprio S. The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethni­city, insulin resistance, and common gene variants. Diabetes Care 2013; 36: 1353-1360.
  21. Nobili V, Alisi A, Grimaldi C, Liccardo D, Francalanci P, Monti L, Castellano A, de Ville de Goyet J. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity? Pediatr Obes 2014; 9: e99-e102
  22. Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoho­lic fatty liver disease: old and new concepts on development, pro­gression, metabolic insight and potential treatment targets. BMC Pediatr 2013; 13:40.
  23. Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its aso­ciation with biochemical and anthropometric measures. Liver Int 2009; 29: 159-163.
  24. Pajuelo J, Cuadros M, Campos M, Sánchez J. Prevalencia de so­brepeso y obesidad en niños menores de cinco años en el Perú 2007-2010. Rev Peru Med Exp Salud Pública 2011; 28: 222-227.
  25. Encuesta Nacional de la Situación Nutricional en Colombia. En: http://www.dane.gov.co/files/investigaciones/boletines/vehicu­los/bol_veh_Itrim11.pdf ICBF 2010. Bogotá.
  26. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Hor­ton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepa­tic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
  27. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-149.
  28. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Be­hling C. Prevalence of fatty liver in children and adolescents. Pe­diatrics 2006; 118: 1388-1393.
  29. Xanthakos S, Miles L, Bucuvalas J, Daniels S, García V, Inge T. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006; 4: 226-232.
  30. Roberts E. Pediatric nonalcoholic fatty liver disease (NAFLD): a “growing” problem? J Hepatol 2007; 46: 1133-1142.
  31. Schwimmer J, McGreal N, Deutsch R, Finegold M, Lavine J. In­fluence of Gender, Race, and Ethnicity on Suspected Fatty Liver in Obese Adolescents. Pediatrics 2005; 115: e561-e566.
  32. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathologi­cal correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500-505.
  33. Pacheco L, Piñeiro LR, Fragoso AT, Valdés AMC, Martínez R. Hígado graso no alcohólico en niños obesos. Rev Cubana Pe­diatr [revista en la Internet] 2006 [citado 2015 Sep; 78. En: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75312006000100002&lng=es].
  34. Pontiles M, Morón A, Rodríguez H, Perdomo G. Prevalencia de la enfermedad de hígado graso no alcohólico en una población de niños obesos en Valencia, Venezuela. Archivos Latinoamericanos de Nutrición 2014; 64: 73-82. En: http://www.alanrevista.org/ ediciones/2014/2/?i=art1.
  35. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
  36. Patton HM Lavine JE, Van Natta ML, Schwimmer JB, Klei­ner D, Molleston J; Nonalcoholic Steatohepatitis Clinical Re­search Network. Clinical correlates of histopathology in pedia­tric nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1961-1971.
  37. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical ap­praisal of current data and implications for future research. J Pe­diatr Gastroenterol Nutr 2006; 43: 413-427.
  38. Quirós-Tejeira RE, Rivera CA, Ziba TT, Mehta N, Smith CW, Butte NF. Risk for nonalcoholic fatty liver disease in Hispanic youth with BMI > or = 95th percentile. J Pediatr Gastroenterol Nutr 2007; 44: 228-236.
  39. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neus­chwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, Purdie DM, Demetris AJ, Clouston AD. Pro­gressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133: 80-90.
  40. Sahoo K, Sahoo B, Choudhury AK, Sofi NY, Kumar R, Bhadoria AS. Childhood obesity: causes and consequences. J Family Med Prim Care 2015; 4:187-192.
  41. Seidell JC. Obesity, insulin resistance and diabetes: a worldwide epidemic. Br J Nutr 2000; 83: S5-S8.
  42. Wiegand S, Keller KM, Röbl M, L’Allemand D, Reinehr T, Wi­dhalm K, Holl RW. APV-Study Group and the German Com­petence Network Adipositas. Obese boys at increased risk for no­nalcoholic liver disease: evaluation of 16.390 overweight or obese children and adolescents. Int J Obes (Lond) 2010; 34: 1468-1474.
  43. Villa A, Della Torre S, Stell A, Cook J, Brown M, Maggi A. Tetra­dian oscillation of estrogen receptor is necessary to prevent liver li­pid deposition. Proc Natl Acad Sci U S A 2012; 109: 11806-11811.
  44. Kelly DM, Nettleship JE, Akhtar S, Muraleedharan V, Sellers DJ, Brooke JC, McLaren DS, Channer KS, Jones TH. Testostero­ne suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sci 2014; 109: 95-103.
  45. Zhang H, Liu Y, Wang L, Li Z, Zhang H, Wu J, Rahman N, Guo Y, Li D, Li N, Huhtaniemi I, Tsang SY, Gao GF, Li X. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. J Lipid Res 2013; 54: 345-357.
  46. Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013; 19: 5219-5238.
  47. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351.
  48. Kanerva N, Sandboge S, Kaartinen NE, Männistö S, Eriksson JG. Higher fructose intake is inversely associated with risk of nonalco­holic fatty liver disease in older Finnish adults. Am J Clin Nutr 2014; 100: 1133-1138.
  49. Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. Nutrients 2014; 6: 5679-5703.
  50. Vos MB. Nutrition, nonalcoholic fatty liver disease and the mi­crobiome: recent progress in the field. Curr Opin Lipidol 2014; 25: 61-66.
  51. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva, World Health Organization 1999.
  52. National Cholesterol Education Program, Executive summary of the third report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
  53. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443.
  54. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide de­finition. Lancet 2005; 366: 1059-1062.
  55. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yec­kel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374.
  56. Castro AL, Arriaga HE, Palacios GC. Esteatosis hepática (EH) como factor asociado a la presencia de riesgo metabólico en escolares y ado­lescentes obesos. Gaceta Médica de México 2014; 150: 95-100.
  57. Maclaren NK, Gujral S, Ten S, Motagheti R. Childhood obesity and insulin resistance. Cell Biochem Biophys 2007; 48: 73-78.
  58. Walenbergh SM, Houben T, Hendrikx T, Jeurissen ML, van Gorp PJ, Vreugdenhil AC, Adriaanse MP, Buurman WA, Hofker MH, Mosca A, Lindsey PJ, Alisi A, Liccardo D, Panera N, Koek GH, Nobili V, Shiri-Sverdlov R. Plasma cathepsin d levels: a no­vel tool to predict pediatric hepatic inflammation. Am J Gastroen­terol 2015; 110: 462-470.
  59. Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 2013; 108: 1526-1531.
  60. Monteiro PA, Antunes B de M, Silveira LS, Christofaro DG, Fernandes RA, Freitas Junior IF. Body composition variables as predictors of NAFLD by ultrasound in obese children and adoles­cents. BMC Pediatr 2014; 14: 25.
  61. Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012; 9: 152-161.
  62. Peña L, Aguiar Santana I, Ruiz Moreno. Esteatosis hepática y es­teatohepatitis En: F Arguelles Martín, MD García Novo, P Pavón Belinchón, E Román Riechmann, G Silva García, A Sojo Aguirre eds. Tratado de Gastroenterología, Hepatología y Nutrición Pe­diátrica aplicada de la Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica. Madrid: Ergon; 2011; 577- 585. ISBN: 978-84-8473-891-6.
  63. Sundaram SS, Zeitler P, Nadeau K. The Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease in children. Curr Opin Pediatr 2009; 21: 529-535.
  64. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Ars­lanian S, Wong G, Bennett P, Shaw J, Caprio S; The metabolic syndrome in children and adolescents – an IDF consensus report. IDF Consensus Group. Pediatr Diabetes 2007; 8: 299-306.
  65. Kurtoğlu S, Hatipoğlu N, Mazıcıoğlu M, Kendirici M, Keskin M, Kondolot M. Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods. J Clin Res Pediatr Endocrinol 2010; 2: 100-106.
  66. Kelly A, Dougherty S, Cucchiara A, Marcus CL, Brooks LJ. Catecho­lamines, adiponectin, and insulin resistance as measured by HOMA in children with obstructive sleep apnea. Sleep 2010; 33: 1185-1191.
  67. Barlow SE. Expert Committee recommendations regarding the pre­vention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120: S164-S192.
  68. Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, Sirlin CB. SAFETY study: alanine aminotransfera­se cut-off values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138: 1357-1364.
  69. Strauss RS, Barlow SE, Dietz WH. Prevelance of abnormal serum aminotransferase values in overweight and obese adolescents. J Pe­diatrics 2000; 136: 727-133.
  70. Cali AM, De Oliveira AM, Kim H, Chen S, Reyes-Mugica M, Escalera S, Dziura J, Taksali SE, Kursawe R, Shaw M, Savoye M, Pierpont B, Constable RT, Caprio S. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 2009; 49: 1896-1903.
  71. Cali AM, Zern TL, Taksali SE, de Oliveira AM, Dufour S, Ot­vos JD, Caprio S. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proathero­genic state. Diabetes Care 2007; 30: 3093-3098.
  72. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138.
  73. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-689.
  74. Wieckowska A, Zein NN, Yerian LM, Wieckowska A, Zein NN, Yerian LM, López AR, McCullough AJ, Feldstein AE. In vivo as­sessment of liver cell apoptosis as a novel biomarker of disease seve­rity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
  75. Feldstein AE, Wieckowska A, López AR, Liu YC, Zein NN, Mc­Cullough AJ. Cytokeratin-18 fragment levels as noninvasive bio­markers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-1078.
  76. Shannon A, Alkhouri N, Carter-Kent C, Monti L, Devito R, López R, Feldstein AE, Nobili V. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr 2011; 53: 190-195.
  77. Kleiner DE,
 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024